

Hsa-miR-194-5p and hsa-miR-195-5p are down-regulated expressed in high dysplasia HPV-Positive Pap-smear samples compared to normal cytology HPV-Positive Pap-smear samples

Ali Dehghani

Tarbiat Modares University

Fardin Khajepour

Kerman University of Medical Sciences

Mohammad Dehghani

Kerman University of Medical Sciences

Ehsan Razmara

Monash University

Mohammadreza Zangouey

Kerman University of Medical Sciences

Maryam Fekri Soofi Abadi

Kerman University of Medical Sciences

Reza Bahram Abadi Nezhad

Rafsanjan University of Medical Sciences

Shahriar Dabiri

Kerman University of Medical Sciences

Masoud Garshasbi (✉ masoud.garshasbi@modares.ac.ir)

Tarbiat Modares University

Research Article

Keywords: Cervical Cancer, Cervical dysplasia, Human Papillomavirus, hsa-miR-194-5p, hsa-miR-195-5p

Posted Date: June 26th, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-3020799/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

The human papillomavirus (HPV) infection may affect the miRNA expression pattern during cervical cancer (CC) development. To demonstrate the association between high-risk HPVs and the development of the cervix dysplasia, we examined the expression patterns of hsa-miR-194-5p and hsa-miR-195-5p in Pap smear samples from southeast Iranian women. We compared samples that were HPV-positive but showed no abnormality in the cytological examination to samples that were HPV-positive and had severe dysplasia.

Methods

Pap smear samples were obtained from 60 HPV-Positive (HPV-16/18) patients with histologically confirmed severe dysplasia (cervical intra-epithelial neoplasia (CIN 3) /carcinoma in situ) and the normal cytology group. The expression of hsa-miR-194-5p and hsa-miR-195-5p was analyzed by real-time quantitative PCR, using specific stem-loop primers and U6 snRNA as the internal reference gene. Clinicopathological features were associated with miRNA expression levels. Furthermore, functional enrichment analysis was conducted using *in silico* tools. Kaplan-Meier survival method was also obtained to discriminate survival significant candidate miRNAs in CC, and receiver operating characteristic (ROC) curves were constructed to assess the diagnostic value.

Results

Compared to HPV-positive cytologically normal Pap smear samples, hsa-miR-194-5p, and hsa-miR-195-5p relative expression decreased significantly in HPV-positive with a severe dysplasia pap smear. Kaplan-Meier analysis indicated a significant association between miR-194 decrease and poor CC survival. In essence, ROC curve analysis showed that miR-194-5p and miR-195-5p could serve as valuable markers for the development of cervix dysplasia in individuals who are positive for high-risk HPVs.

Conclusions

This study revealed that hsa-miR-194-5p and hsa-miR-195-5p may possess tumor suppressor capabilities in the context of cervical dysplasia progression. However, it remains uncertain whether these microRNAs are implicated in the transition of patients with high dysplasia to cervical cancer. We also showed the potential capability of candidate miRNAs as novel diagnostic biomarkers related to cervical dysplasia progression.

Introduction

Cervical cancer (CC) is a leading cause of mortality in women worldwide and represents a substantial global health challenge. In 2020, more than 604,000 new cases were detected worldwide, and about 342,000 women died, primarily middle-aged (1).

CC typically does not cause any symptoms in its early stages. However, as the cancer advances, it may lead to several noticeable symptoms, such as irregular vaginal bleeding, pelvic pain, and changes in the color or odor of vaginal discharge. These symptoms typically coincide with abnormal changes in the microscopic appearance of the cells on the surface of the cervix (2). Although the exact etiology of CC is unknown, infection with the Human Papillomavirus (HPV), smoking, impaired immunity, as well as other risk factors have been linked to this disease (3). CC is a multifactorial condition attributed to environmental, genetic, and epigenetic factors (4).

The conventional Papanicolaou (Pap) smear test has been a gold standard in screening cervical pre-malignant and malignant conditions since the 1950s. However, due to low sensitivity and considerable false negative rate of cytological examinations, the US Preventive Services Task Force recommended a combination of cytology and molecular HPV evaluation (co-testing)(5). Women worldwide continue to suffer from CC despite significant advances in screening methods in recent years (6). Thus, a better understanding of the processes behind CC progression is critical to find a conscious and solid method to improve CC diagnosis. Also, CC can be more effectively treated if precancerous lesions are found in early stages via cytological screening and CC-related molecular tests (7).

In numerous human cases, high-risk (HR) HPV infections (including HPV16 and HPV18) are identified as substantial risk factors for CC development (8). Long-term misexpression of HR HPV E6 and E7 oncogenes contributes to CC development (9). These oncogenes trigger neoplastic cell transformation primarily because of genetic and epigenetic instability. On top of that, HPV E6 and E7 inactivate tumor suppressor genes p53 and retinoblastoma (Rb), respectively (10). As a result of DNA damage, p53 expression increases, which causes G1 cell cycle arrest. As a result of this pause, DNA can be repaired, or apoptosis can be triggered in some cases(11). Dephosphorylated Rb controls cell-cycle progression by inactivating growth-improving proteins such as E2F-1 and c-Myc transcription factors. Therefore, Rb functions to limit growth in normal cells, while its inactivation/absence in cancer cells promotes uncontrolled proliferation (12). In addition to targeting tumor suppressors p53 and Rb, HPV can cause several cellular and molecular changes, such as genetic and epigenetic remodeling during CC progression (13).

Several studies have demonstrated that microRNAs play a significant role in epigenetic remodeling (14). These molecules are short single-stranded RNAs with about 22 nucleotides that negatively modulate post-transcriptional gene expression by targeting the 3'-untranslated mRNAs, resulting in destruction or translational suppression (15). Moreover, they have been the subject of much research in cancer research, not only because they can function as oncogenes or tumor suppressor genes but also because they function within gene regulatory networks that control carcinogenesis through specific targets or signal pathways. They are involved in a variety of human malignancies because of their sine quo non roles (16).

Recently, several miRNAs have been abnormally expressed during CC development, including miRNA-944, miRNA-155, and miR-449b (Table 1) (17–19). Additionally, various microRNAs exhibit distinct expression patterns between HR-HPV-positive CC cells and HPV-negative CC cells, as well as normal cervical tissues,

throughout different stages of the disease. This implies that HR-HPV-encoded proteins may directly influence miRNA expression within the host cell which are essential to maintain a transformed phenotype and subsequent progress to invasive carcinoma (20). Moreover, the expression of mature miRNAs uniquely differs at different phases of CC development (21). The findings suggest that CC may benefit from identifying numerous aberrantly expressed miRNAs induced by HR-HPV infection, which could be useful in early detection.

Table 1
Differentially expressed profile microRNAs in normal and CC tissues or cells.

MicroRNAs expression	CC/ Normal tissue or cell	Reference
miR-26a, miR-143, miR-145, miR-99a, miR-203, miR-513, miR-29a, miR-199a, miR-106a, miR-205, miR-197, miR-16, miR-27a, miR-142-5p	Downregulated	<i>Pereira et al.(32)</i>
miR-21, miR-25, miR-106a, miR-10a, miR-185, miR-20b, miR-27a, miR-146a	Upregulated	<i>Shen et al.(82)</i>
miR-375, miR-203, miR-34a, miR-23b, miR-100, miR-145, miR-424, miR-193b, miR-497	Downregulated	
miR-181d; miR-181c, miR-191; miR-425, miR-132, miR-429; miR-200a; miR-200b, let-7e; miR-99b; miR-125a, miR-106b; miR-93; miR-25, miR-141; miR-200c, miR-98; let-7f-2, miR-215; miR-194-1, miR-29c; miR-29b-2, miR-30e; miR-30c-1, miR-18a; miR-92a-1; miR-17; miR-19a; miR-19b-1; miR-20a	Upregulated	<i>Sharma et al.(83)</i>
miR-212; miR-497, miR-143; miR-145, miR-100;	Downregulated	
miR-4484, miR-3162-5p, miR-3147, miR-2392, miR-1290, miR-1286, miR-641, miR-503, miR-432, miR-375, miR-373, miR-372, miR-324-5p, miR-224, miR-210, miR-203, miR-196a, miR-199a, miR-193b, miR-185, miR-183, miR-146, miR-133b	Upregulated	<i>Banno et al.(84)</i>
miR-574, miR-495, miR-487b, miR-455, miR-450, miR-424, miR-422a, miR-376a, miR-218, miR-214, miR-149, miR-145, miR-143, miR-138, miR-126, miR-124, miR-30b, miR-29a, miR-10b, miR-7, miR-1	Downregulated	
miR-155, miR-92a, miR-92b, miR-224, miR-221, miR-222, miR-31, miR-182, miR-106a, miR-17, miR-20a, miR-20b, miR-15b, miR-16, miR-25, miR-185, miR-93	Upregulated	<i>Li et al. (85)</i>
miR-7b, miR-145, miR-126, miR-199a-3p, miR-195, miR-29a, miR-375, miR-10b, miR-29c, miR-218, miR-424, miR-100, miR-125, miR-99a	Downregulated	

Two cancer-associated miRNAs, hsa-miR-194-5p and hsa-miR-195-5p, have been identified to be dysregulated in different malignancies, such as colon and prostate cancer, indicating they may act as potential diagnostic and prognostic biomarkers. Hsa-mir-194-5p expression is dysregulated in multiple malignancies and plays either as a tumor-suppressive or oncogenic factor in different cancers (22). Hsa-

mir-194-5p can also interact with essential signaling pathways in CC, such as the Wnt and Hippo signaling pathways (23). p53 family members, directly affected by HPV oncogenes in CC development, are in the identical cluster with hsa-miR-194-5p in mammalian genomes (24). Also, hsa-miR-195-5p is a miR-15/16 family member and may show some anti-cancer properties. However, this miRNA is downregulated in various cancers, such as melanoma, laryngeal, and colorectal cancer (25–27). Furthermore, overexpression of the oncogene E2F transcription factor 3 (E2F3) promotes the development of different cancers and is related to HPV *E6* and *E7* oncogenes (28). Studies have shown that miR-194-5p and miR-195-5p inhibit Wnt, Hippo, and PI3K signaling pathways related to CC progression and development. These miRNAs have also been shown to affect E2F3 directly, making them ideal candidates for this study (26, 29).

With the aim of investigating the potential impact of Hsa-miR-194-5p and hsa-miR-195-5p on CC progression, this study sought to evaluate the expression levels of these candidate microRNAs in Pap smear samples harboring HPV-16/18 infections and presenting normal cytology or severe dysplasia. The findings of this investigation shed light on the potential role of these microRNAs in cervical carcinogenesis, revealing new avenues for further research into the molecular mechanisms underpinning this devastating disease.

Materials and Method

Sample procurement

In this study, 60 HPV positive Liquid Based Cytology (LBC) samples (39 HPV16 and 21 HPV18) were collected from women with suspected cervical cancer from 2019 to 2021 at Afzalipour Hospital, Kerman, Iran. Ayre spatulas were used to obtain Pap smear samples from the surface of the cervix and its surrounding area. Of note, the patients received no prior pretreatment.

Inclusion criteria were as follows: i) all patients must have been infected with HPV16/18, which was confirmed by an HPV DNA test (INNO-LiPA® HPV Genotyping Extra II kit; product number: 81534), and exclusion criteria were: i) individuals who had received radiation and chemotherapy before collecting specimens, ii) individuals suffering from acute organ failure, iii) individuals who are cognitively and communicatively impaired.

Three pathologists evaluated all cases, and cytological outcomes were classified based on Bethesda classification (30).

Written consent was obtained from all individuals. All participants were also informed that all clinical data would be used only for scientific research. The Tarbiat Modares University Ethics Committee approved the study under the following ID: IR.MODARES.REC.1400.306. This investigation was also carried out based on the principles of the Declaration of Helsinki.

After applying exclusion criteria and microscopic examination, a total of 60 Pap smear samples were selected and classified into two groups: 1) the normal cytology group consists of 20 HPV16 and 10 HPV18; 2) the severe dysplasia (cervical intra-epithelial neoplasia 3 (CIN3)) group consists of 19 HPV16 samples and 11 HPV18 (each group, 30 samples). Then, samples were sent to the Stem Cell and Pathology Research Center, Kerman, Iran, for further analysis.

RNA isolation

Total RNA was extracted from LBC samples using Trizol (15596026, Invitrogen™, Carlsbad, CA, USA). RNA quality was verified by agarose gel electrophoresis, and its purity was confirmed by the relative absorbance ratio at A260/280 and A260/230 using Nanodrop 2000 (Thermo Scientific™, USA); the acceptable ratio fell within the range of 1.8 to 2.0. Due to RNA instability, the obtained samples were instantly used for cDNA synthesis (Thermo Scientific™). RNase-free conditions were maintained throughout the procedure.

cDNA Synthesis

Stem-loop primers were specifically designed for cDNA synthesis using miRNA sequence data from the miRbase database and the 44 nucleotide stem-loop structure developed by *Chen et al* (31). An extra six nucleotides were appended to the 5' end of the stem-loop sequence. These additional nucleotides were designed to have a sequence that is the reverse complement of the 3' end of the target microRNA. The physical properties of the resulting oligo sequences were then assessed using the OligoAnalyzer Tool (Table 2). PCR primers for hsa-miR-194-5p, hsa-miR-195-5p, and U6 snRNA were obtained from SinaClon Company, Tehran, Iran. Due to the steady expression of U6 small nuclear RNA in cervical tissues, it was chosen as the endogenous reference in this study (32).

Table 2
the sequence of used primers

Selected miRNAs	Sequence	
Hsa- mir-194-5P	RT	5' GTCGTATGCAGTGCAGGGTCCGAGGTATTCGCACTGCATACGACTCCACA 3'
	F	5' CACCATGTAACAGCAACTCC 3'
	R	5' GTGCAGGGTCCGAGGT 3'
Hsa- mir-195-5P	RT	5' GTCGTATGCAGTGCAGGGTCCGAGGTATTCGCACTGCATACGACGCCAAT 3'
	F	5' AGAGAAGTAGCAGCACAGAAA 3'
	R	5' GTGCAGGGTCCGAGGT 3'
U6 snRNA	RT	5' GTGCAGGGTCCGAGGTTTGGACCATTCTCGAT 3'
	F	5' GGAACGATACAGAGAAGATTAGCA 3'
	R	5' GTGCAGGGTCCGAGGT 3'

The manufacturer's directions are to be followed (Thermo Scientific RevertAid First Strand cDNA Synthesis Kit): 1 µg of obtained RNA was added to 4 µl 5x buffer, 1 µl reverse transcriptase enzyme, 1 µl of each miRNA cDNA synthesis specific primer, 2 µl dNTPs, and 10 µL RNase-free water to adjust the reaction volume to 20 µL. The combination was incubated in a thermal cycler at 44°C for 60 min. To inactivate the reverse transcriptase enzyme, the mixture was kept for five minutes at 85°C. Until needed, the cDNAs were stored at -20°C.

RT-qPCR

RT-qPCR was carried out by the Qiagene thermo-cycler (Rotor-Gene Q). The final volume was 20 µl including 10 µl RealQ Plus 2× Master Mix Green (Ampliqon, Denmark), 1 µl of each forward and reverse primer, 2 µl undiluted cDNA, and 6 µl RNase-free water to adjust the reaction volume to 20 µL. Rotor-Gene Q PCR cycling was used with the following steps: a 15-minute denaturation at 95°C, followed by 40 cycles of amplification at 95°C for 15 seconds, 58°C for 30 seconds, and 72°C for 30 seconds.

Absolute quantification is not always required for miRNA expression analysis, as relative quantification can still provide valuable insights into differential expression patterns between sample groups. Moreover, absolute quantification often requires more starting material and may be more susceptible to variations in experimental conditions, leading to potential inaccuracies in the results. The $2^{-\Delta\Delta C_T}$ method was used in this study for analyzing RT-qPCR results. First, the average cycle threshold (Ct) values were calculated for the internal control and miRNAs. The Ct value is a cycle in which the fluorescence level reaches a certain amount. ΔC_t was the difference between the Ct values of each miRNA and the reference gene. $2^{-\Delta C_t}$, an expression of two studied miRNAs between our groups, was used (33).

Hsa-miR-194-5p and Hsa-miR-195-5p functional enrichment

A DNA Intelligent Analysis (DIANA)-miRPath v3.0 program was used to characterize the functional properties of miRNAs (DIANA Lab, Thessaly, Greece) (34). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, which the (DIANA fully supports)-miRPath v3.0 database, was used to reach a better understanding of the function of dysregulated miRNAs and their putative shared targets (35). The validated target pathways of hsa-miR-194-5p and hsa-miR-195-5p were identified using the algorithms of miRTarBase v7.0 and DIANA-microT-CDS. DIANA-microT-CDS v5.0 algorithm is designed to recognize miRNA targets both in the 3' untranslated regions and in coding sequences, based on complementary pairing with nucleotides in positions 1–9 at the miRNA 5' end (Based on complex physical models and/or machine learning approaches, microT-CDS can currently identify miRNA-gene interactions only in 3' UTR and CDS regions). *P*-value and the false discovery rate < 0.05 were determined.

Survival analysis by Kaplan-Meier plotter

Using a Kaplan-Meier survival plot, the relationship between hsa-miR-194-5p and hsa-miR-195-5p expression and overall survival of CC was examined. Kaplan-Meier Plotter database, as a broadly used online database, was used to evaluate the link between miRNA expressions and tumor prognosis. This database contains useful and reliable information from GEO, The European Genome-phenome Archive (EGA), and TCGA. In order to reach the OS plot, we uploaded each miRNA into the Kaplan-Meier database. The OS plot was calculated by analyzing 307 CC samples by miRpower for the pan-cancer tool of the Kaplan-Meier plotter (36). Since the patients in this study were unavailable, these 307 CC samples were solely included in the Kaplan-Meier database. Log-rank *P*-values, hazard ratios, and 95% confidence intervals were calculated.

Statistical Analysis

Due to our study's relatively small sample size, the Shapiro-Wilk test was used to evaluate whether data followed a normal distribution. In all groups, the data distribution had a non-normal distribution. Hence, the Mann-Whitney test was used to examine differences in the mean between miRNAs (hsa-miR-194-5p and hsa-miR-195-5p) expression and ΔC_t in cervical cancer samples, HPV-positive with normal and dysplasia. GraphPad Prism version 9 was used for statistical analysis. Receiver operating characteristic (ROC) curves were constructed to evaluate the sensitivities and specificities of the candidate miRNAs. The area under the ROC curves (AUC) was calculated for the prediction of cut-off values of the markers. A significant level was defined as a *P*-value of less than 0.05 for all tests.

Results

The expression levels of hsa-miR-194-5p and hsa-miR-195-5p decreased in CC patients

As an effective approach, integrative computational bioinformatics procedures were used to detect nominate miRNAs using large-scale expression profiling data and low-throughput experimental verification. Moreover, according to the literature review, the proposed possible targets, and the earlier scientific discoveries about contributing miRNAs to CC progression, we selected hsa-miR-194-5p and hsa-miR-195-5p as candidate miRNAs.

According to the literature review, mature miR-194 and miR-195 were expressed ubiquitously in all samples. Thus, their expression was normalized using U6 snRNA. RT-qPCR was used to examine the expression status of these miRNAs between HPV-Positive Pap smear samples with severe dysplasia and cytologically normal HPV-Positive samples as control. Hsa-miR-194-5p (fold change: -2.628, $P < 0.0001$) and hsa-miR-195-5p (fold change: -1.584, $P < 0.0001$) were significantly down-regulated in samples with severe dysplasia compared with controls Fig. 1a **and b**. Unsupervised hierarchical cluster analysis revealed that the pattern of significantly lower expression of selected miRNAs in Pap smear samples could be used to distinguish progressive cervical lesions from HPV-Positive cytologically normal samples Fig. 1c. Comparisons between patients' demographic and clinical data are shown in Table 3.

Table 3
comparison of patient's general information using the Chi-Square experiment

		Cellular changes		χ^2	P-Value
		Normal	Severe		
Age	≤ 45	11(36.7%)	14(46.7%)	0.617	0.432
	> 45	19(63.3%)	16(53.3%)		
Active Smoker	No	20(66.7%)	23(76.7%)	0.738	0.39
	Yes	10(33.3%)	7(23.3%)		
Family History of CC	No	22(73.3%)	22(73.3%)	0.000	1.000
	Yes	8(26.7%)	8(26.7%)		
Marital Status	Single	1(3.3%)	4(13.3%)	1.963	0.161
	Married	29(96.7%)	26(86.7%)		

Hsa-miR-194-5p and hsa-miR-195-5p target prediction and linked pathways

In the current study, we used DIANA-miRPath v3.0 (<http://www.microrna.gr/miRPathv3>), an online software package designed to evaluate miRNA regulatory roles and identify controlled pathways. More than 600 000 miRNA targets have been experimentally supported in DIANA-TarBase v7.0. In order to compare the results of DIANA-TarBase v7.0 with high-quality in silico predicted targets, we additionally employ DIANA-microT-CDS(37). We also used DIANA-miRPath v. 3.0 software to undertake a computational target prediction study and a pathway analysis. We illustrated the shared pathways

between hsa-miR-194-5p and hsa-miR-195-5p using the programs of miRTarBase v. 7.0 and DIANA-microT-CDS (v5.0). The paths are clustered according to significance levels, and the findings are presented as heatmaps in Figs. 2a and b. MirTargetLink 2.0 (38) was used to map the anticipated mRNA targets of the verified miRNAs. There were no valid overlapped gene targets between the miRNAs (Fig. 3a and b).

Hsa-miR-194 is correlated with poor overall survival in CC patients

Since our data supported that hsa-miR-194 and hsa-miR-195 expression is downregulated with advanced stage of cervical dysplasia and they may target some critical gene and signaling pathway, we hypothesized whether these miRNAs expression levels affect CC patients' survival or not. We evaluated the predictive value of selected miRNA using the Kaplan-Meier plotter database on previous patient datasets. Survival curves were plotted for CC individuals (36). Interestingly, data showed that OS was low in individuals with lower expression of hsa-miR-194. We also found that the median survival time of CC patients with low miR-194 expression was 27.9 months ($p < 0.01$), which was significantly shorter than those with higher miR-194 expression, 48.43 months ($p < 0.01$, false discovery rate (FDR) < 0.3 , no analysis restriction was applied). According to previous studies, the low expression of miR-194 in different malignancies, such as colorectal and breast cancer, is inversely correlated with patient survival rate (39).

The relation between the downregulation of the hsa-miR-195 and overall CC poor survival was insignificant. The duration of follow-up threshold was set at 200 months. The graphs showed that as the CC progresses, the OS diminishes (Fig. 4). It should be considered that the Kaplan-Meier plotter does not distinguish between the - 5p and 3p forms of the microRNAs.

Diagnostic value of miR-194-5p and miR-195-5p in CC

To evaluate the diagnostic value of a miRNA expression signature in cervical dysplasia development, ROC curve analysis was done. According to the ROC curves, results (based on the sensitivity and specificity of miRNA expression) indicated that the AUCs were 0.840 ($P < 0.0001$) and 0.825 ($P < 0.0001$) for miR-194-5p and miR-195-5p, respectively (Fig. 5a and 5b). At the cut-off value of 0.41, the optimal sensitivity and specificity for miR-194-5p were 80% and 90% (95% confidence interval (CI) = 0.727–0.953), respectively. At the cut-off value of 0.695, both sensitivity and specificity for miR-195-5p were 83.33% (95% CI = 0.712–0.937).

Discussion

CC is a genetic and pathologic condition in which dysregulation of miRNAs may play a key role in different aspects of cancer hallmarks (40). To diagnose precancerous cervical lesions, many techniques (e.g., Pap smear, colposcopy, and biopsy) are now widely used (41, 42). However, the limited specificity

and sensitivity of these approaches and their invasive nature are key drawbacks (41, 43). Therefore, this malignancy remains one of the world's most significant health issues because most HR HPV infections present with no symptoms after one to two years (44).

The dysregulation of miRNAs has been firmly established in various stages of under-developed CC patients, indicating their critical involvement in the development of this disease (45). According to Wilting *et al.*, chromosomal instability alters miRNA expression at different stages of cancer growth (46). Studies suggest a correlation between viral oncoproteins and the dysregulation of miRNAs in various stages of cervical dysplasia, which may contribute to the development and progression of CC (47). HPV-induced cell transformation requires the viral oncoproteins E6 and E7. E6 induces the proteolytic degradation of the p53 tumor suppressor protein, which plays a vital role in the transcription of numerous coding and non-coding genes. Also, E7 inhibits the retinoblastoma tumor suppressor from releasing E2F from the pRb–E2F complex; thus, HPV E6/E7 can modulate miRNA expressions (8).

Since miRNAs are more stable and accessible to detect than mRNA, they may be a promising candidate for cancer diagnosis (48). A computational bioinformatics approach has been used to identify miRNAs that may contribute to CC development. As a logical strategy, candidate miRNAs (hsa-miR-194-5p and hsa-miR-195-5p) were chosen using preliminary detection of candidate miRNAs derived from large-scale expression profile data and low-throughput experimental verification for the selected miRNAs. In addition, hsa-miR-194-5p and hsa-miR-195-5p target members of the E2F transcription factor family and p53, a tumor suppressor protein (49, 50). In addition, early research indicates that hsa-miRNA-194-5p and hsa-miRNA-195-5p play an instrumental role in many signaling pathways commonly dysregulated in different stage of CC development, including Wnt, PI3K, and Hippo signaling pathways (23, 51). Most cancer and miRNA investigations are conducted on cell lines and tissue specimens. While these studies have considerably helped raise the scientific findings on cancer, using tissue for cancer diagnosis is an invasive procedure. To our knowledge, no published report on Pap smear samples using RT-qPCR to analyze hsa-miR-194-5p and hsa-miR-195-5p expression in HPV-positive patients with normal cytology and pre-malignant lesions.

Hsa-miR-194-5p and hsa-miR-195-5p may target some critical genes related to HPV infection and cancer progression, according to the bioinformatics predictions. Using DIANA-miRPath v3.0 and miRTargetLink 2.0, we suggested *E2F6*, *anterior gradient 2 (AGR2)*, and *ITCH* (also known as atrophin1-interacting protein 4; AIP4) as a putative target for hsa-miR-194-5p and hsa-miR-195-5p. E2F6 is a member of polycomb complexes and attaches to repressed chromatin, and is essential for cell fate and cell proliferation (52). In addition, McLaughlin-Drubin *et al.* provided evidence that HPV E7 interacts with and functionally deregulates the E2F family member *E2F6* (53). While other research indicates that hsa-miR-195-5p can interact with various genes (such as *NEK2*, *LOXL2*, *YAP1*, and *PFKFB4*) in CC, the decrease of its expression was consistent across all investigations and among us (50). Furthermore, down-regulation of the hsa-miR-194-5p expression was closely associated with E2F3 up-regulation and node metastasis in bladder cancer (29).

Abnormal hyperplasia of the cervical squamocolumnar (SC) junction, vulnerable to HR-HPV, strongly correlates with CC. The Liu *et al.* study revealed that the SC junction marker *AGR2* is overexpressed during the CC progression (54). Interestingly, Li *et al.* showed that *AGR2* could be negatively regulated by hsa-miR-194-5p in colorectal cancer (55).

ITCH belongs to the Nedd4-like family of E3 ubiquitin ligases and plays a crucial role in tumorigenesis (56). Zhou *et al.* identified a gradually increased expression of *ITCH* during CC tumorigenesis, which negatively correlated with large tumor suppressor 1 (LATS1, a critical tumor suppressor in CC) (57). Yes-associated protein (YAP), a key downstream effector of the Hippo signaling pathway, is phosphorylated by activated LATS1, which causes this protein to get degraded (58). Furthermore, based on miRTarBase v7.0 and microT-CDS v5.0 algorithms, the Hippo signaling pathway and the WNT signaling pathway overlapped between our candidate miRNAs. According to He *et al.*, YAP expression significantly increased as CC progressed. They also confirmed that YAP overexpression is directly related to the HPV16 E6 oncoprotein (59), indicating that the Hippo signaling pathway could be crucial in CC development. YAP may also be directly targeted by hsa-miR-194-5p and hsa-miR-195-5p and negatively regulated by them (60, 61).

Mutated/deregulated Wnt signaling components are extensively characterized in CC; HPV E6 oncoprotein can also stimulate the Wnt signaling pathway using a variety of mechanisms, highlighting the great importance of the Wnt signaling pathway in CC development (62). Previous studies demonstrated that hsa-miR-194-5p and hsa-miR-195-5p could deregulate the Wnt/ β -catenin pathway in various cancers (63, 64). Overall, we believe that hsa-miR-194-5p and hsa-miR-195-5p modulate *E2F6*, *AGR2*, and *ITCH* to perform their activities in HPV-positive under-development CC patients. Moreover, the hippo and Wnt signaling pathways are common target pathways among our candidate miRNAs. However, more functional experiments of modulating hsa-miR-194-5p and hsa-miR-195-5p is needed to confirm.

ROC curve analysis was used to evaluate the diagnostic accuracy of the candidate miRNAs. These results are consistent with earlier research showing that miR-194-5p and miR-195-5p expression is downregulated in various malignancies (65), suggesting them as a probable diagnostic marker for CC. According to data from the Kaplan-Meier plotter online database, low expression of hsa-miR-194 is associated with poor survival in CC patients. Several malignancies, including colorectal and ovarian cancer, have a poor prognosis related to hsa-miR-194 reduction (39, 66). It is important to note that the Kaplan-Meier plotter analysis does not distinguish between the 5p and 3p forms of the microRNAs. In a study conducted by Azimi *et al.*, it was observed that the level of miR-195-3p (2.82, $P = 0.01$) in Pap smear samples was significantly higher in patients with high-grade squamous intraepithelial lesions (HSIL) compared to those with low-grade squamous intraepithelial lesions (LSIL) (67). Considering these facts, it makes sense that the Kaplan Meier plotter did not show a significant association between miR-195-5p reduction and overall poor survival in CC.

According to the literature, hsa-miR-194-5p and hsa-miR-195-5p are frequently dysregulated in numerous malignancies and can operate as tumor suppressors (68, 69). It was discovered in the study of Song *et al.*

that hsa-miR-195-5p functions as a tumor suppressor in CC, and its expression in CC tissues and cell lines decreased compared with control groups (70). Additionally, *Yang et al.*'s investigation revealed that miR-195 expression in CC tissues is markedly downregulated in the early stages of CC (71). These are entirely in line with our findings in Pap smear samples. There was also a study that examined the relationship between hsa-miR-195-5p, *MMP14* (matrix metalloproteinases 14), and *HDGF* (hepatocellular growth factor) (70, 72). Interestingly, *MMP14* (a significant contributor to the invasion and migration of CC cells) and *HDGF* (an overexpressed transcription factor in CC) can insert their effects through the Rb-E2f pathway (70). The downregulation of hsa-miR-195-5p results in the overexpression of *MMP14* and *HDGF*, which act as tumor promoters and are both targeted by hsa-miR-195-5p. As the expression of ADP-ribosylation factor-like 2 (*ARL2*) decreases, hsa-miR-195-5p limits CC cell malignancy. (73). In another scenario, the plasmacytoma variant translocation 1 gene, considered an oncogenic long-noncoding RNA, is induced by the HPV16 E7 gene, significantly reducing the number of hsa-miR-195-5p expression (74). Therefore, hsa-miR-195-5p inhibits CC formation by targeting various downstream proteins and can act as a tumor-suppressor agent. In our study, hsa-miR-195-5p expression was significantly decreased in HPV-positive with severe dysplasia LBCs compared to HPV-positive LBCs with normal cytology.

Hsa-miR-194-5p is downregulated in glioma and targets *Bmi1* to decrease epithelial-to-mesenchymal transition. This miRNA is also downregulated in colorectal cancer (CRC) and targets *KLK10* to inhibit its proliferation, verifying its tumor-suppressive roles (75, 76). In prostate cancer, on the other hand, hsa-miR-194-5p is increased and downregulates *SOCS2* to promote cancer development (77). Zhang *et al.* discovered that the SLC16A1-AS1 long non-coding RNA sponges hsa-miR-194-5p and the downregulation of this long non-coding RNA in cervical cancer leads to hsa-miR-194-5p overexpression, which improves cancer cell development by *SOCS2* downregulation (78). These findings contradicted our findings, showing a significant drop in hsa-miR-194-5p expression in HPV-positive cytologically abnormal LBCs compared to HPV-positive LBCs with normal cytology. Hsa-miR-194-5p seems to be a target for P53 that modulates some p53 biological actions, including induction of growth arrest and apoptosis (79). The HPV E6 protein forms a compound with the cellular proteins E6-AP and p53, allowing p53 to be degraded more quickly through the ubiquitin-dependent proteolytic pathway (80). Therefore, it is tempting to believe that hsa-miR-194-5p has tumor-suppressive properties in HPV-positive CC. However, few studies show how hsa-miR-194-5p plays during CC development. Still, one scenario based on Wang *et al.*'s study on prostate cancer suggests that downregulation of hsa-miR-194-5p is linked to overexpression of the oncogene E2F transcription factor 3 (E2F3), which can improve cancer progression (29, 81). Because the E2F transcription factor family is targeted by viral oncoprotein E7, we hypothesized that hsa-miR-194-5p could also play a tumor-suppressive role in CC.

Conclusion

In essence, evaluating the expression level of the hsa-miR-194-5p and hsa-miR-195-5p in HPV-Positive cytologically abnormal LBCs compared to HPV-Positive LBCs with normal cytology in women from the south-east of Iran was a fresh idea in this investigation. There was a significant reduction of the selected miRNAs in severe dysplasia cytology HPV-Positive samples compared to HPV-Positive samples with

normal cytology, proposing their tumor-suppressive potential role in CC. However, we need more research to determine how HPV-related progression in CC works. Future research could confirm their tumor-suppressive properties by modulating hsa-miR-194-5p and hsa-miR-195-5p in CC cells.

Abbreviations

CC: cervical cancer

HPV: Human papillomavirus

HR-HPV: high-risk HPV

Rb: retinoblastoma

LBC: Liquid based cytology

CIN3: Cervical intra-epithelial neoplasia 3

Ct: cycle threshold

EGA: European Genome-phenome Archive

ROC: Receiver operating characteristic

AUC: the area under the ROC curves

FDR: False discovery rate

AGR2: anterior gradient 2

AIP4: atrophin1-interacting protein 4

SC: squamocolumnar

LATS1: large tumor suppressor 1

HSIL: high-grade squamous intraepithelial lesions

LSIL: low-grade squamous intraepithelial lesions

MMP14: matrix metalloproteinases 14

HGDF: hepatocellular growth factor

ARL2: ADP-ribosylation factor-like 2

CRC: colorectal cancer

Declarations

Consent for Publication:

Not applicable

Ethics approval and consent to participate:

Written consent was obtained from all individuals. All participants were also informed that all clinical data would be used only for scientific research. The Tarbiat Modares University Ethics Committee approved the study under the following ID: IR.MODARES.REC.1400.306

Availability of data and material

The data can be made available upon reasonable request from the Corresponding author.

Competing interests:

The authors declare that they have no conflict of interest.

Funding:

Not applicable

Authors' contributions:

MG and SD conceived and planned the experiments. AD carried out the experiments. MZ, FK, and ER planned and carried out the data analyses. AD, MFSA contributed to sample preparation. AD, RABN, and MG contributed to the interpretation of the results. AD took the lead in writing the manuscript. MD and SD carried out clinical analyses. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

Acknowledgments

We express our gratitude to the patients and their families included in this study.

References

1. Guimarães YM, Godoy LR, Longatto-Filho A, Reis Rd. Management of Early-Stage Cervical Cancer: A Literature Review. *Cancers*. 2022;14(3):575.
2. Divine LM, Huh WK. Tertiary Prevention of Cervical Cancer. *Clin Obstet Gynecol*. 2014;57(2).
3. Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. *Chin J Cancer Res*. 2020;32(6):720.

4. Moore EE, Wark JD, Hopper JL, Erbas B, Garland SM, CeCaGeEn Study G. The roles of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. *Twin Res Hum Genet.* 2012;15(1):79–86.
5. Force UPST. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2018;320(7):674–86.
6. Pisarska J, Baldy-Chudzik K. MicroRNA-based fingerprinting of cervical lesions and cancer. *J Clin Med.* 2020;9(11):3668.
7. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. *Am J Clin Pathol.* 2012;137(4):516–42.
8. Lei J, Ploner A, Lagheden C, Eklund C, Nordqvist Kleppe S, Andrae B, et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. *PLoS Med.* 2018;15(10):e1002666.
9. García A, Maldonado G, González JL, Svitkin Y, Cantú D, García-Carrancá A et al. High-risk human papillomavirus-18 uses an mRNA sequence to synthesize oncoprotein E6 in tumors. *Proceedings of the National Academy of Sciences.* 2021;118(41).
10. Tang S, Tao M, McCoy JP Jr, Zheng Z-M. The E7 oncoprotein is translated from spliced E6* I transcripts in high-risk human papillomavirus type 16-or type 18-positive cervical cancer cell lines via translation reinitiation. *Journal of virology.* 2006;80(9):4249-63.
11. Peng X, Zhang Y, Gao J, Cai C. MiR-1258 promotes the apoptosis of cervical cancer cells by regulating the E2F1/P53 signaling pathway. *Exp Mol Pathol.* 2020;114:104368.
12. Tzenov YR, Andrews PG, Voisey K, Popadiuk P, Xiong J, Popadiuk C, et al. Human papilloma virus (HPV) E7-mediated attenuation of retinoblastoma (Rb) induces hPygopus2 expression via Elf-1 in cervical cancer. *Mol Cancer Res.* 2013;11(1):19–30.
13. Chen J, Deng Y, Ao L, Song Y, Xu Y, Wang CC, et al. The high-risk HPV oncogene E7 upregulates miR-182 expression through the TGF- β /Smad pathway in cervical cancer. *Cancer Lett.* 2019;460:75–85.
14. Ferreira P, Roela RA, Lopez RVM, Estevez-Diz MDP. The prognostic role of microRNA in epithelial ovarian cancer: A systematic review of literature with an overall survival meta-analysis. *Oncotarget.* 2020;11(12):1085.
15. Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. *Front Genet.* 2019;10:478.
16. Li Y, Li C, Li D, Yang L, Jin J, Zhang B. lncRNA KCNQ10T1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. *OncoTargets and therapy.* 2019;12:2649.
17. Park S, Kim J, Eom K, Oh S, Kim S, Kim G, et al. microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. *BMC Cancer.* 2019;19(1):1–8.

18. Liu X, Zhou Y, Ning Y-e, Gu H, Tong Y, Wang N. MiR-195-5p inhibits malignant progression of cervical cancer by targeting YAP1. *OncoTargets and therapy*. 2020;13:931.
19. Cheng L, Shi X, Huo D, Zhao Y, Zhang H. MiR-449b-5p regulates cell proliferation, migration and radioresistance in cervical cancer by interacting with the transcription suppressor FOXP1. *Eur J Pharmacol*. 2019;856:172399.
20. Wang Y, Xu B, Shen X, Sun L. Diagnostic value of miR-153 and miR-203 in patients with cervical cancer and their correlation with human papillomavirus infection. *Am J Translational Res*. 2021;13(8):9736.
21. Hoelzle CR, Arnoult S, Borém CRM, Ottone M, de Magalhães KCSF, da Silva IL, et al. MicroRNA Levels in Cervical Cancer Samples and Relationship with Lesion Grade and HPV Infection. *MicroRNA*. 2021;10(2):139–45.
22. Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. *Mol Cancer*. 2019;18(1):28.
23. Yang F, Xiao Z, Zhang S. Knockdown of miR-194-5p inhibits cell proliferation, migration and invasion in breast cancer by regulating the Wnt/ β -catenin signaling pathway. *Int J Mol Med*. 2018;42(6):3355–63.
24. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. *Hepatology*. 2010;52(6):2148–57.
25. Chai L, Kang X-J, Sun Z-Z, Zeng M-F, Yu S-R, Ding Y, et al. MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells. *Cancer Manage Res*. 2018;10:989.
26. Zhou M, Wang Y, Zhang C, Qi M, Yao M, Sun L, et al. MicroRNA–195–5p suppresses the proliferation, migration, invasion and epithelial–mesenchymal transition of laryngeal cancer cells in vitro by targeting E2F3. *Experimental and Therapeutic Medicine*. 2021;22(4):1–8.
27. Li B, Wang S, Wang S. MiR-195 suppresses colon cancer proliferation and metastasis by targeting WNT3A. *Mol Genet Genomics*. 2018;293(5):1245–53.
28. Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, et al. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. *Mod Pathol*. 2019;32(2):290–305.
29. Wang Y, Sun G, Wang C, Guo W, Tang Q, Wang M. MiR-194-5p inhibits cell migration and invasion in bladder cancer by targeting E2F3. *J buon*. 2018;23(5):1492–9.
30. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA*. 2002;287(16):2114–9.
31. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem–loop RT–PCR. *Nucleic Acids Res*. 2005;33(20):e179–e.
32. Wang X, Tang S, Le S-Y, Lu R, Rader JS, Meyers C, et al. Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth. *PLoS ONE*.

2008;3(7):e2557.

33. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. *Nat Protoc.* 2008;3(6):1101–8.
34. Rafiee R, Razmara E, Motavaf M, Mossahebi-Mohammadi M, Khajehsharifi S, Rouhollah F et al. Circulating serum miR-1246 and miR-1229 as diagnostic biomarkers in colorectal carcinoma. 2022.
35. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, et al. DIANA-miRPath v3. 0: deciphering microRNA function with experimental support. *Nucleic Acids Res.* 2015;43(W1):W460–W6.
36. Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes. *Sci Rep.* 2021;11(1):1–10.
37. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. *Nucleic Acids Res.* 2015;43(W1):W460–W6.
38. Kern F, Aparicio-Puerta E, Li Y, Fehlmann T, Kehl T, Wagner V, et al. miRTargetLink 2.0—interactive miRNA target gene and target pathway networks. *Nucleic Acids Res.* 2021;49(W1):W409–W16.
39. Wang B, Shen Z-l, Gao Z-d, Zhao G, Wang C-y, Yang Y, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. *Cell Cycle.* 2015;14(7):1046–58.
40. Causin RL, Freitas AJAd TH, Filho CM, Reis Rd, Reis RM, Marques MMC. A systematic review of microRNAs involved in cervical cancer progression. *Cells.* 2021;10(3):668.
41. Amatullah M, Begum SA. Evaluation of coloscopic and Pap's smear findings among visual inspection with acetic acid cases in detection of precancerous lesion of cervix against histopathology: Colposcopy and Pap smear evaluation. *Bangladesh Med Res Counc Bull.* 2019;45(2):103–7.
42. Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. *J Clin Oncol.* 2015;33(1):83.
43. Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WGV, Wheeler CM. New technologies in cervical cancer screening. *Vaccine.* 2008;26:K42–K52.
44. Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? *Clin Microbiol Infect.* 2015;21(9):817–26.
45. Shen S, Zhang S, Liu P, Wang J, Du H. Potential role of microRNAs in the treatment and diagnosis of cervical cancer. *Cancer Genet.* 2020;248:25–30.
46. Wilting SM, Snijders PJF, Verlaet W, Jaspers A, van de Wiel MA, van Wieringen WN, et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. *Oncogene.* 2013;32(1):106–16.
47. Wang X, Chang C, Jin W, Arun A, Sudunabuqi S, Aodaofu A et al. Identifying Key MicroRNAs Targeted by Narenmandula in a Rodent Nephropathy Model. *Evidence-Based Complementary and Alternative*

Medicine. 2020;2020.

48. Zheng M, Hou L, Ma Y, Zhou L, Wang F, Cheng B, et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. *Mol Cancer*. 2019;18(1):1–8.
49. Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. *Cancer Cell*. 2010;18(4):367–81.
50. Xu Q, Xu J-L, Chen W-Q, Xu W-X, Song Y-X, Tang W-J, et al. Roles and mechanisms of miR-195–5p in human solid cancers. *Biomed Pharmacother*. 2022;150:112885.
51. Sun M, Song H, Wang S, Zhang C, Zheng L, Chen F, et al. Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer. *J Hematol Oncol*. 2017;10(1):1–16.
52. Cartwright P, MuÈller H, Wagener C, Holm K, Helin K. E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. *Oncogene*. 1998;17(5):611–23.
53. McLaughlin-Drubin ME, Huh K-W, Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. *J Virol*. 2008;82(17):8695–705.
54. Liu N, Wu W, Gao H, He Q, Zhu Y, Wei Z et al. AGR2: A Potential Diagnostic Biomarker for Cervical Cancer. Available at SSRN 3478113. 2019.
55. Li J, Hu J, Luo Z, Zhou C, Huang L, Zhang H, et al. AGR2 is controlled by DNMT3a-centered signaling module and mediates tumor resistance to 5-Aza in colorectal cancer. *Exp Cell Res*. 2019;385(1):111644.
56. Larson VA, Tang Q, Ständer S, Kang S, Kwatra SG. Association between itch and cancer in 16,925 patients with pruritus: Experience at a tertiary care center. *J Am Acad Dermatol*. 2019;80(4):931–7.
57. Zhou Y, Tao F, Cheng Y, Xu F, Yao F, Feng D et al. Up-regulation of ITCH is associated with down-regulation of LATS1 during tumorigenesis and progression of cervical squamous cell carcinoma. *Clin Invest Med*. 2014:E384–E94.
58. Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. *EMBO Rep*. 2014;15(6):642–56.
59. He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. *EMBO Mol Med*. 2015;7(11):1426–49.
60. Jung KH, McCarthy RL, Zhou C, Uprety N, Barton MC, Beretta L. MicroRNA Regulates Hepatocytic Differentiation of Progenitor Cells by Targeting YAP1. *Stem Cells*. 2016;34(5):1284–96.
61. Yu S, Jing L, Yin XR, Wang MC, Chen YM, Guo Y, et al. MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. *Oncotarget*. 2017;8(59):99757–71.
62. Zhang R, Lu H, Lyu Y-y, Yang X-m, Zhu L-y, Yang G-d, et al. E6/E7-P53-POU2F1-CTHRC1 axis promotes cervical cancer metastasis and activates Wnt/PCP pathway. *Sci Rep*. 2017;7(1):44744.

63. Peng Y, Zhang X, Ma Q, Yan R, Qin Y, Zhao Y, et al. MiRNA-194 activates the Wnt/ β -catenin signaling pathway in gastric cancer by targeting the negative Wnt regulator, SUFU. *Cancer Lett.* 2017;385:117–27.
64. Chen S, Wang L, Yao X, Chen H, Xu C, Tong L, et al. miR-195-5p is critical in REGy-mediated regulation of wnt/ β -catenin pathway in renal cell carcinoma. *Oncotarget.* 2017;8(38):63986–4000.
65. Yen Y-T, Yang J-C, Chang J-B, Tsai S-C. Down-Regulation of miR-194-5p for Predicting Metastasis in Breast Cancer Cells. *Int J Mol Sci.* 2022;23(1):325.
66. Nakamura K, Sawada K, Miyamoto M, Kinose Y, Yoshimura A, Ishida K, et al. Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression. *Oncotarget.* 2019;10(6):673.
67. Azimi T, Paryan M, Mondanizadeh M, Sarmadian H, Zamani A. Pap Smear miR-92a-5p and miR-155-5p as potential diagnostic biomarkers of squamous intraepithelial cervical cancer. *Asian Pac J Cancer Prev.* 2021;22(4):1271–7.
68. Jiang M-j, Chen Y-y, Dai J-j, Gu D-n, Mei Z, Liu F-r, et al. Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer. *Mol Cancer.* 2020;19(1):1–15.
69. Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. *Mol Cancer.* 2019;18(1):1–19.
70. Song R, Cong L, Ni G, Chen M, Sun H, Sun Y, et al. MicroRNA-195 inhibits the behavior of cervical cancer tumors by directly targeting HDGF. *Oncol Lett.* 2017;14(1):767–75.
71. Yang X, Yan Z, Yang H, Ni H, Zhang L, Wang Y. Clinical value of combined detection of miR-1202 and miR-195 in early diagnosis of cervical cancer. *Oncol Lett.* 2019;17(3):3387–91.
72. Li M, Ren C-X, Zhang J-M, Xin X-Y, Hua T, Wang H-B, et al. The effects of miR-195-5p/MMP14 on proliferation and invasion of cervical carcinoma cells through TNF signaling pathway based on bioinformatics analysis of microarray profiling. *Cell Physiol Biochem.* 2018;50(4):1398–413.
73. Pan SS, Zhou HE, Yu HY, Xu LH. MiR-195-5p inhibits the cell migration and invasion of cervical carcinoma through suppressing ARL2. *Eur Rev Med Pharmacol Sci.* 2019;23(24):10664–71.
74. Shen C-J, Cheng Y-M, Wang C-L. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. *J Drug Target.* 2017;25(7):637–44.
75. Zhang X, Wei C, Li J, Liu J, Qu J. MicroRNA-194 represses glioma cell epithelial-to-mesenchymal transition by targeting Bmi1. *Oncol Rep.* 2017;37(3):1593–600.
76. Liu T, Fang Y. MiR-194-3p modulates the progression of colorectal cancer by targeting KLK10. *Histol Histopathol.* 2021:18413.
77. Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, et al. MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. *Cancer Res.* 2017;77(4):1021–34.

78. Zhang H, Jin S, Ji A, Ma Y, Zhang C, Wang A, et al. LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis. *Cancer Manag Res.* 2021;13:1299–306.
79. Georges SA, Biery MC, Kim S-y, Schelter JM, Guo J, Chang AN, et al. Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215. *Cancer Res.* 2008;68(24):10105–12.
80. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. *Proc Natl Acad Sci U S A.* 2000;97(15):8501–6.
81. Ma C, Han J, Dong D, Wang N. MicroRNA-152 suppresses human osteosarcoma cell proliferation and invasion by targeting E2F transcription factor 3. *Oncol Res.* 2018;26(5):765.
82. Shen S, Zhang S, Liu P, Wang J, Du H. Potential role of microRNAs in the treatment and diagnosis of cervical cancer. *Cancer Genet.* 2020;248–249:25–30.
83. Sharma G, Dua P, Mohan Agarwal S. A comprehensive review of dysregulated miRNAs involved in cervical cancer. *Curr Genom.* 2014;15(4):310–23.
84. Banno K, Iida M, Yanokura M, Kisu I, Iwata T, Tominaga E, et al. MicroRNA in Cervical Cancer: OncomiRs and Tumor Suppressor miRs in Diagnosis and Treatment. *Sci World J.* 2014;2014:178075.
85. Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. *J Pathol.* 2011;224(4):484–95.

Figures




Figure 1

candidate miRNAs expression profile in the HPV-Positive Pap smear samples of patients with normal cytology and severe dysplasia. (a and b) expression analysis indicated a significant down-regulation of hsa-miR-194-5p (fold change: -2.628, P < 0.0001) and hsa-miR-195-5p (fold change: -1.584, P < 0.0001) in the HPV-Positive patients with severe dysplasia compared to normal cytology controls. (c) HPV-positive individuals with severe dysplasia and normal cytology were distinguished using unsupervised hierarchical cluster analysis employing differentially expressed miRNAs. Red indicates miRNAs with relatively high expression, while miRNAs with low relative expression are shown in green on the heatmap (Euclidian distance, complete linkage). Heatmapper (<http://www.heatmapper.ca>) was used to make the heatmap.




Figure 2

Heatmap representing differently expressed miRNAs against substantially enriched functional networks. (a) Hierarchical clustering results for each miRNAs and their relevant pathways are shown. Hippo signaling pathway and adherens junction pathway were overlapped pathways between candidate miRNAs. The figure depicted is based on the online output of Diana miRpath V.2 using the algorithm of miRTarBase v7.0. (b) Predicted pathways heat map DIANA-microT-CDS (v5.0) algorithm. Based on this algorithm, the wnt signaling pathway and signaling pathways regulating the pluripotency of stem cells were common among candidate miRNAs. Lower P values (more significant) and higher interplay of each miRNA with a particular molecular pathway are indicated by reddish color combinations in the heatmap.




Figure 3

miRNAs validated and predicted target genes. (a) the strong interplay of hsa-miR-195-5p with its validated target genes provided by miRTargetLink 2.0 Human. (b) The same network depicted for hsa-miR-194-5p. (c) After predicted interaction comparison, E2F6, AGR2, and ITCH genes have remained. hsa-miR-194-5p and hsa-miR-195-5p did not show any strong and weak interaction in this network (weak and predicted interactions are not depicted here).




Figure 4

Kaplan-Meier survival curve indicates the prognostic value of the hsa-mir-194 in CC using the Pan-cancer analysis in mirPower, which is a part of the Kaplan-Meier plotter database to analyze the prognostic value of the desired miRNAs in a different type of cancer over time, p-value > 0.05 (a) Downregulation of the hsa-mir-194 is related to the poor overall survival of CC. High expression of hsa-miR-194 was identified in 127 patients, while 180 patients showed low expression for this miRNA. (b) hsa-mir-195-5p was not a reliable prognostic biomarker in CC (hazard ratio; 95% and confidence interval showed in parentheses).




Figure 5

ROC curves were constructed to indicate miR-194 (a) and miR-195 (b) AUCs. (a) At the cut-off value of 0.41 for hsa-miR-194-5p, the sensitivity was 80%, and the specificity was 90% with an AUC of 0.84 (95% CI = 0.727–0.935). (b) At the cut-off value of 0.695 for hsa-miR-195-5p, the sensitivity, and specificity were 83.33 (95% CI = 0.712–0.937).